New drug duo tested for tough liver disease
NCT ID NCT04594694
Summary
This study tested whether combining two drugs, obeticholic acid and bezafibrate, could better control Primary Biliary Cholangitis (PBC), a chronic liver disease. It was for patients whose standard treatment wasn't working well or who couldn't tolerate it. The main goal was to see if the combination improved key liver blood test results over 12 weeks. The trial was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academisch Medisch Centrum
Amsterdam, 1105 AZ, Netherlands
-
Artroscan s.r.o., Gastroenterologicka ambulance
Ostrava, 722 00, Czechia
-
Budai Hepatologiai Centrum (BHC)
Budapest, 1111, Hungary
-
CHRU de Lille
Lille, 59000, France
-
CHU Paris Est - Hopital Saint Antoine
Paris, Paris 12, France
-
Centre Hospitalier Universitaire Grenoble
Grenoble, 38043, France
-
Clinical Hospital Dubrava
Zagreb, 10000, Croatia
-
Consorcio Hospital General Universitario
Valencia, 46010, Spain
-
DEOEC II. sz. Belgyógyászati Klinika
Debrecen, 4032, Hungary
-
Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa
Larissa, 41110, Greece
-
Flinders Medical Centre
Bedford Park, Perth, 5042, Australia
-
Fundacio Clinic Per La Recerca Biomedica
Barcelona, 08036, Spain
-
Groupe Hospitalier Pitié Salpêtrière - Assistance publique - Hôpitaux de Paris
Paris, 75651, France
-
Hadassah Ein-Karem Medical Center - Liver unit
Jerusalem, 91120, Israel
-
Hepato-Gastroenterologie HK, s.r.o.
Hradec Králové, 500 12, Czechia
-
Hospital of Lithuanian University of Health Sciences, Kauno Klinikos
Kaunas, 50161, Lithuania
-
Hull University Teaching Hospitals NHS Trust
Hull, HU3 2JZ, United Kingdom
-
Hôpital Henri Mondor
Créteil, 940000, France
-
Institute of Cellular Medicine, Newcastle University
Newcastle upon Tyne, NE2 4HH, United Kingdom
-
John Radcliffe Hospital
Oxford, OX3 9DU, United Kingdom
-
Kyungpook National University Hospital
Daegu, 41944, South Korea
-
Medizinische Hochschule Hannover
Hanover, 30625, Germany
-
Narodowy Instytut Onkologii, Klinika Gastroenterologii Onkologicznej
Warsaw, 02-781, Poland
-
Pusan National University Hospital
Busan, 602-739, South Korea
-
Research Site s.r.o.
Pilsen, 301 00, Czechia
-
Royal Adelaide Hospital
Adelaide, 5000, Australia
-
Tartu University Hospital
Tartu, 51014, Estonia
-
Tel Aviv Surasky Medical Center
Tel Aviv, 6423906, Israel
-
UZ Gasthuisberg
Leuven, 3000, Belgium
-
Universitatsklinikum Hamburg-Eppendorf UKE
Hamburg, 20246, Germany
-
Universitetet i Oslo - Akershus Universitetssykehus (AHUS)
Loerenskog, 1478, Norway
-
Vlinius University
Vilnius, 08661, Lithuania
-
Zagreb University Hospital Center
Zagreb, 10000, Croatia
Conditions
Explore the condition pages connected to this study.